BioCentury
ARTICLE | Clinical News

Lilly, ArQule jockey for best-in-class next-gen Btk inhibitor at ASH

November 6, 2019 11:07 PM UTC

While investors punished ArQule on Phase I data for ARQ 531, the Bruton’s tyrosine kinase inhibitor was tested in a slightly sicker population than Lilly's competing LOXO-305, and each company used different endpoints, making it difficult to declare an early winner.

Data were reported in abstracts released ahead of the American Society of Hematology (ASH) meeting in December. ...